Global and India GLP-1 Weight Loss Drug Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global and India GLP-1 Weight Loss Drug Market Report & Forecast 2024-2034
GLP-1 (Glucagon-Like Peptide-1) weight loss drugs are a class of drugs used to treat obesity and control weight. GLP-1 is a naturally occurring insulin-releasing hormone produced by cells in the small intestine after food ingestion and has multiple physiological effects, including stimulating insulin secretion and inhibiting gastric emptying, thereby slowing the passage of food through the gastrointestinal tract. GLP-1 weight loss drugs simulate the biological activity of GLP-1 and trigger a series of physiological reactions, which help reduce appetite, increase satiety, and reduce calorie intake, thereby helping people lose weight. This class of drugs is often used to treat obesity, especially in obese patients who are at risk for diabetes.
The global GLP-1 Weight Loss Drug revenue was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during the forecast period (2024-2034).
In India, the GLP-1 Weight Loss Drug revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period (2024-2034).
The global key players of GLP-1 Weight Loss Drug include Novo Nordisk, AstraZeneca, Eli Lilly, Sanofi, BENEMAE, HANSOH PHARMLA, CHIATAI TIANQING, Tonghua Dongbao Pharmaceutical and Huadong Medicine, etc. The global five biggest players hold a share of % in 2022.
This report focuses on global and India GLP-1 Weight Loss Drug market, also covers the segmentation data of other regions in regional level and county level.
India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2024, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.
India is a market full of opportunities, and the demand for GLP-1 Weight Loss Drug will continue to grow rapidly in the future.
Global GLP-1 Weight Loss Drug Scope and Market Size
GLP-1 Weight Loss Drug market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global GLP-1 Weight Loss Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2029.
For India market, this report focuses on the GLP-1 Weight Loss Drug market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in India.
Novo Nordisk
AstraZeneca
Eli Lilly
Sanofi
BENEMAE
HANSOH PHARMLA
CHIATAI TIANQING
Tonghua Dongbao Pharmaceutical
Huadong Medicine
Segment by Type
Injection
Oral
Online Pharmacy
Offline Pharmacy
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces GLP-1 Weight Loss Drug definition, global sales (volume and revenue), India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of GLP-1 Weight Loss Drug companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of GLP-1 Weight Loss Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, GLP-1 Weight Loss Drug sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
The global GLP-1 Weight Loss Drug revenue was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during the forecast period (2024-2034).
In India, the GLP-1 Weight Loss Drug revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period (2024-2034).
The global key players of GLP-1 Weight Loss Drug include Novo Nordisk, AstraZeneca, Eli Lilly, Sanofi, BENEMAE, HANSOH PHARMLA, CHIATAI TIANQING, Tonghua Dongbao Pharmaceutical and Huadong Medicine, etc. The global five biggest players hold a share of % in 2022.
This report focuses on global and India GLP-1 Weight Loss Drug market, also covers the segmentation data of other regions in regional level and county level.
India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2024, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.
India is a market full of opportunities, and the demand for GLP-1 Weight Loss Drug will continue to grow rapidly in the future.
Global GLP-1 Weight Loss Drug Scope and Market Size
GLP-1 Weight Loss Drug market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global GLP-1 Weight Loss Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2029.
For India market, this report focuses on the GLP-1 Weight Loss Drug market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in India.
By Company
Novo Nordisk
AstraZeneca
Eli Lilly
Sanofi
BENEMAE
HANSOH PHARMLA
CHIATAI TIANQING
Tonghua Dongbao Pharmaceutical
Huadong Medicine
Segment by Type
Injection
Oral
Segment by Application
Online Pharmacy
Offline Pharmacy
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces GLP-1 Weight Loss Drug definition, global sales (volume and revenue), India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of GLP-1 Weight Loss Drug companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of GLP-1 Weight Loss Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, GLP-1 Weight Loss Drug sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices